CSO
+47 993 73 473

Dr. Stern is co-founder of UniTargeting Research and has more than 25 years experience in industrial application of the UTR technology. Dr. Stern has many years of scientific experience from the Max Planck Institute of Biochemistry, Martinsried, Germany, and the Universities of Hamburg and Munich, Germany, and Bergen, Norway, where she holds an Associate Professor position in Molecular Biology.

Dr. Sterns primary areas of expertice is related to posttranscriptional regulation in mammalian cells.

CTO
+47 414 34 433

Dr. Løvlie is co-founder of ColoAlert, a molecular test for colorectal cancer. Dr Løvlie has more than 25 years of experience as leading scientist within the biotech industry, and has served as CTO in several life science-focused businesses.

Dr Løvlie’s primary areas of expertise is related to extraction of nucleic acids from clinical samples and development of diagnostic tests.

CEO
+47 906 26 870

Hans Hekland has 30 years of experence from international business development and corporate finance in industry and venture capital. He has implemented several financial transactions such as stock exchange listings and M&As, and has served as executive director at medical and life science-focused businesses and as a venture capital investor.

Primary areas of expertise include financial due diligence and finance, strategy, and business development in the healthcare segment.

CHAIRMAN - PROFESSOR OF MEDICINE
+47 920 45 491

Dr Øgreid is co-founder of ColoAlert, and has 40 years of scientific, clinical, administrative and commercial experience.
He has served as executive director for medical and life science-focused businesses and as a venture capital investor.

Dr Øgreids primary areas of expertise include research of genetic pathways in colorectal carcinogenesis and development of tests to diagnose early colorectal cancer.